RobertBLorsbachMD

Pathology • Cincinnati, OH

Hematopathology, Anatomic Pathology, Clinical Pathology

Associate Professor, Pathology, University of Arkansas COM

Join to view full profile

Dr. Lorsbach is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lorsbach's full profile

Already have an account?

Office
3333 Burnet Ave
ML 1010
Cincinnati, OH 45229
Phone+1 513-636-4261

Fax+1 513-636-3026

Education & Training

Brigham and Women's HospitalFellowship, Hematopathology, 1998 - 1999
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 1994 - 1998
University of Kansas School of MedicineClass of 1994

Certifications & Licensure

OH State Medical License 2014 - 2026
AR State Medical License 2006 - 2014
TN State Medical License 1999 - 2007
MA State Medical License 1998 - 2000
American Board of Pathology Anatomic Pathology
American Board of Pathology Hematology

Publications & Presentations

PubMed

7 citations
Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
Eily Cournoyer, Justin Ferrell, Susan Sharp, Anish Ray, Michael Jordan
Haematologica. 2024-04-01
26 citations
Hematologic Complications with Age in Shwachman-Diamond Syndrome.
Elissa Furutani, Shanshan Liu, Ashley Galvin, Sarah K. Steltz, Maggie Malsch
Blood Advances. 2021-11-10
66 citations
ALK+ histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.
Paul Geraeds Kemps, Jennifer Picarsic, Benjamin H. Durham, Zofia Hélias-Rodzewicz, Laura Sophia Hiemcke-Jiwa
Blood. 2021-11-02

Abstracts/Posters

Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR)
Robert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
Robert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental Delay
Robert B. Lorsbach, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019